We will be contrasting the differences between Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and TG Therapeutics Inc. (NASDAQ:TGTX) as far as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics Inc.	N/A	0.00	38.89M	-1.77	0.00
TG Therapeutics Inc.	N/A	4309.21	173.48M	-2.08	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Aldeyra Therapeutics Inc. and TG Therapeutics Inc.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics Inc.	0.00%	-99.8%	-85.2%
TG Therapeutics Inc.	0.00%	-185%	-127.1%

Volatility & Risk

Aldeyra Therapeutics Inc. has a 0.79 beta, while its volatility is 21.00%, thus making it less volatile than Standard & Poor’s 500. Competitively, TG Therapeutics Inc. is 114.00% more volatile than Standard & Poor’s 500, because of the 2.14 beta.

Liquidity

Aldeyra Therapeutics Inc.’s Current Ratio and Quick Ratio are 4.8 and 4.8 respectively. The Current Ratio and Quick Ratio of its competitor TG Therapeutics Inc. are 2.7 and 2.7 respectively. Aldeyra Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to TG Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for Aldeyra Therapeutics Inc. and TG Therapeutics Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Aldeyra Therapeutics Inc.	0	0	2	3.00
TG Therapeutics Inc.	0	0	2	3.00

Aldeyra Therapeutics Inc.’s consensus price target is $29, while its potential upside is 268.96%. Competitively the consensus price target of TG Therapeutics Inc. is $17.5, which is potential 118.75% upside. Based on the analysts view we can conclude, Aldeyra Therapeutics Inc. is looking more favorable than TG Therapeutics Inc.

Institutional & Insider Ownership

Aldeyra Therapeutics Inc. and TG Therapeutics Inc. has shares held by institutional investors as follows: 76.1% and 66.1%. Aldeyra Therapeutics Inc.’s share held by insiders are 0.94%. Insiders Comparatively, held 0.5% of TG Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aldeyra Therapeutics Inc.	4.71%	-9.19%	-11.11%	3.23%	-4.19%	-3.61%
TG Therapeutics Inc.	37.7%	66.59%	34.45%	-45.58%	-52.57%	66.59%

For the past year Aldeyra Therapeutics Inc. has -3.61% weaker performance while TG Therapeutics Inc. has 66.59% stronger performance.

Summary

Aldeyra Therapeutics Inc. beats TG Therapeutics Inc. on 6 of the 8 factors.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.